Core Insights - The pharmaceutical and biotechnology sector experienced a decline, with the pharmaceutical index dropping by 2.71% from January 31 to February 6, underperforming the Shanghai Composite Index by 1.44 percentage points [4] - The innovative drug sector showed relative resilience, with the innovative drug index (BK1106) increasing by 0.11% during the same period [4] - The market is witnessing a shift in investment focus towards clinical viability and financial sustainability rather than just pipeline quantity and novelty [7] Market Performance - The pharmaceutical and biotechnology index fell by 2.71%, while the Hang Seng Healthcare Index decreased by 1.37% [4] - The innovative drug ETF in Hong Kong (513120) also saw a decline of 0.47% [4] - Notable stock movements included Guangsheng Tang, which surged by 29.83% due to positive clinical trial news, and Changshan Pharmaceutical, which faced a decline due to credit risks and expected losses [5] Clinical Trials and Approvals - A total of 101 clinical trial registrations were disclosed, with 34 trials in Phase II or above [8] - Three innovative drugs received approval, including a new oral drug for moderate to severe ulcerative colitis by Cloudtop New Medicine [12][14] - Johnson & Johnson is exploring an upgraded treatment regimen for inoperable stage III non-small cell lung cancer, aiming to enhance the standard treatment protocol [15] Investment Trends - The investment environment for innovative drugs is becoming more rational, focusing on clinical certainty, commercial viability, and cash flow health [7] - The overall pharmaceutical industry has seen a 3.28% increase since the beginning of 2026, outperforming the CSI 300 index, with significant growth in hospital services, offline pharmacies, and outsourced drug development [5] New Drug Developments - The approval of the new drug by Cloudtop New Medicine addresses a significant unmet need in the treatment of ulcerative colitis, with a growing patient population expected to reach approximately 1.5 million by 2031 [13] - The drug is designed to provide rapid efficacy and deep mucosal healing, which is crucial for improving patient quality of life [14]

Group 1 - The core point of the article is that Innovent Biologics has entered into a strategic partnership with Eli Lilly to advance global research and development of innovative drugs in oncology and immunology, with potential financial benefits amounting to $88.5 billion [1][4]. - Innovent will receive an upfront payment of $350 million and could earn up to $8.5 billion in milestone payments, along with a share of net sales outside Greater China [1][4]. - The Hong Kong Stock Connect Innovative Drug ETF (520880) is fully invested in innovative drug R&D companies and has shown strong performance, leading its peers since 2025 [1][4]. Group 2 - The ETF's index is characterized by high purity, elasticity, and sharpness, demonstrating strong offensive capabilities in the innovative drug rebound market [1][4]. - The top ten constituent stocks of the ETF account for over 73% of its weight, indicating a concentrated representation of the core strength in innovative drug development [1][4]. - The ETF has recorded varying returns over the past five years, with a notable increase of 66.32% in one of the periods analyzed [1][4].

Group 1 - A-shares experienced narrow fluctuations, with the Sci-Tech Innovation Board performing well, particularly in AI applications and computing power chips [1][25] - The Hong Kong stock market saw a significant rebound in the pharmaceutical sector, with the Hong Kong Innovation Drug ETF (520880) reaching a peak increase of 3.86% and closing up 2.9% [3][29] - The Hong Kong Medical ETF (159137) also performed well, gaining 2.1% and achieving six consecutive days of increases [3][29] Group 2 - The innovation drug sector is benefiting from a surge in business development (BD) overseas and commercial success, with major collaborations announced, including a partnership between Innovent Biologics and Eli Lilly worth up to $8.85 billion [6][29] - Over 70% of innovative drug companies are expected to achieve positive revenue growth in 2025, with notable companies like BeiGene reporting revenues exceeding 36 billion yuan [7][30] - The Chinese innovative drug industry is entering a phase of commercial success and internationalization, with a focus on the entire industry chain, including CXO and research services [7][30] Group 3 - ByteDance's recent releases, including the Seedance 2.0 video generation model and the Seedream 5.0 image generation model, have positively impacted the Sci-Tech Artificial Intelligence ETF (589520), which saw a price increase of 1.81% [10][31] - The ETF's composition includes significant holdings in domestic AI companies, with ByteDance accounting for over 29% of the index [11][35] - Analysts are optimistic about AI investment opportunities, citing increased capital expenditures from tech giants and a growing demand for AI applications [11][35] Group 4 - The semiconductor and storage chip sectors are experiencing a "super cycle," with companies like Chipone Technology reaching historical highs [15][38] - The global memory price is expected to surge by 80% to 90% in Q1 2026, driven by AI demand, with the storage market projected to reach $551.6 billion [17][39] - The semiconductor equipment industry is also on the rise, with total sales expected to grow by 26% in 2026, indicating a strong market outlook [17][40]

Group 1 - The core viewpoint is that the Hong Kong pharmaceutical sector is experiencing a strong resurgence, driven by the innovative drug industry chain, particularly led by Innovent Biologics [1][8] - The Hong Kong Stock Connect Innovative Drug ETF (520880) reached a peak of 3.86% and closed up 2.9%, recovering the 20-day moving average with a trading volume of 590 million yuan [1][8] - The Hong Kong Stock Connect Medical ETF (159137), which has a high CXO content, rose by 2.1%, marking its sixth consecutive day of gains [1][8] Group 2 - The Chinese innovative drug sector is witnessing a robust international expansion, with significant business development (BD) transactions occurring [4][10] - Notable collaborations include Innovent Biologics' announcement of a global strategic partnership with Eli Lilly worth up to $8.85 billion, including an upfront payment of $350 million [4][10] - In January, CSPC Pharmaceutical Group entered a platform-level collaboration with AstraZeneca valued at up to $18.5 billion, while Rongchang Biologics secured a $5.6 billion licensing deal with AbbVie, showcasing the global competitiveness of Chinese innovative drugs [4][10] Group 3 - The Chinese innovative drug industry is entering a commercialization phase, with over 70% of innovative drug companies achieving positive revenue growth by 2025 [5][11] - BeiGene reported revenue exceeding 36 billion yuan, demonstrating strong commercialization capabilities [5][11] - Leading companies like Innovent Biologics and Rongchang Biologics have achieved annual breakeven, while Elysium has reported over 2 billion yuan in net profit attributable to shareholders, indicating a transition from R&D investment to performance realization [5][11] Group 4 - Open Source Securities expresses a positive outlook on the innovative drug sector and its supply chain (CXO + research services), as well as emerging national strategic industries such as AI, brain-computer interfaces, and biomanufacturing [5][11] - The Hong Kong pharmaceutical sector has adjusted for nearly two quarters, presenting an attractive investment opportunity [5][11] - Investors are encouraged to consider the Hong Kong Stock Connect Innovative Drug ETF (520880) and its associated funds, which focus on innovative drug research companies, with the top ten weighted stocks accounting for over 73% [5][11]

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical industry [1] Core Insights - The A-share innovative drug sector saw a decline of 1.32% this week, outperforming the CSI 300 index by 0.02 percentage points, while the biopharmaceutical sector rose by 0.04% [2][14] - The Hong Kong innovative drug sector decreased by 1.45%, outperforming the Hang Seng Index by 1.57 percentage points [19] - The XBI index in the US increased by 0.64%, with a cumulative increase of 47.35% over the past six months [3][19] Summary by Sections A-share and Hong Kong Innovative Drug Sector Performance - A total of 56 stocks rose and 88 stocks fell in the innovative drug sector across mainland China and Hong Kong [2] - The top three gainers were China Antibody-B (+22.79%), Yiteng Jiahe (+14.00%), and Nuocheng Jianhua (+12.24%) [2][13] - The bottom three performers were Yaojie Ankang-B (-14.58%), Shuanglu Pharmaceutical (-13.95%), and Xin Nuowei (-12.53%) [2][13] Recent Approvals and Clinical Trials - In February, four innovative drugs were approved for market in China, with no new indications approved [4][22] - In the US, one NDA was approved, with no BLA approvals reported [5][40] - No innovative drugs were approved in Europe or Japan during this period [5][29][34] Global Innovative Drug Transactions - A total of 19 significant transactions occurred globally, with four notable deals disclosed [6][43] - Key transactions included a $1.5 billion agreement between Saintgen Biotech and Genentech, and a $388 million deal between Fuhong Hanlin and Eisai [6][43] Market Data - The total market capitalization of the pharmaceutical industry is approximately 53,087.87 billion [11] - The industry P/E ratio (TTM) stands at 37.3, compared to the CSI 300's P/E ratio of 14.0 [11]

2月10日，A股主要指数窄幅震荡整理，科创综指相对较强；港股早盘一度走高，随后涨幅有所收窄。 具体来看，沪指盘中在4100点上方窄幅震荡，科创综指相对较强，盘中一度涨超1%。截至收盘，沪指涨0.13%报4128.37点，深证成指微涨0.02%，创业板 指跌0.37%，科创综指涨0.31%，沪深北三市合计成交约2.12万亿元，较此前一日减少逾1400亿元。 A股市场超3100股飘绿，酿酒、食品饮料、零售等消费板块集体下挫，电力、有色等板块均走低；传媒板块全线爆发，短剧游戏、影视股表现亮眼，荣信 文化、中文在线、捷成股份等连续两日20%涨停，光线传媒（300251）亦大单封涨停；创新药概念拉升，广生堂涨超10%，万邦德涨停。值得注意的是， 长飞光纤今日再度涨停，股价突破200元大关，续创历史新高。 传媒板块盘中全线爆发，短剧游戏、影视股等表现亮眼。截至收盘，捷成股份、荣信文化、中文在线等连续两日20%涨停，读客文化、幸福蓝海、光线传 媒亦20%涨停，华策影视涨近18%，此外，还有欢瑞世纪、读者传媒、中国电影等约20股10%涨停。 | 代码 名称 | 涨幅% | 现价 | 不正失 | 兴价 | 卖价 | 总量 | ...

1. Report Industry Investment Rating - Not provided in the given content 2. Core Viewpoints of the Report - The report focuses on constructing multiple ETF portfolios, including macro industry, macro + momentum industry, core - satellite, and trinity style rotation portfolios, aiming to find better investment opportunities by combining macro factors, momentum factors, and style rotation [4][5]. - Different industries have different sensitivities to economic, liquidity, and credit factors. For example, traditional cycle industries are sensitive to the economy, TMT is sensitive to liquidity, and consumption is sensitive to credit [4]. 3. Summary According to Relevant Catalogs 3.1 ETF Portfolio Construction Methods 3.1.1 Based on Macro Method - Calculate macro - sensitivities of broad - based, industry - themed, and Smart Beta ETFs based on economic, liquidity, and credit variables. Combine with momentum indicators for complementary analysis [4]. - Traditional cycle industries are suitable for economic up - periods, TMT for weak - economy but loose - liquidity periods, and consumption for credit - expansion periods. State - owned enterprises and ESG - related themes have low sensitivities to liquidity and credit [4]. - Construct three ETF portfolios (macro industry, macro + momentum industry, and core - satellite) and adjust positions monthly [4]. 3.1.2 Trinity Style Rotation ETF Portfolio Construction - Build a medium - to - long - term style rotation model centered on macro - liquidity, and compare it with the CSI 300 index [5]. - Construct three types of models (growth/value rotation, market - cap, and quality models) by screening macro, fundamental, and market - sentiment factors. The model has 8 style - preference results [5]. - Select ETFs with high exposure to the target style, control industry exposure, and set allocation limits to get the final ETF allocation model [5]. 3.2 Macro Industry Portfolio - Select industry - themed ETFs with over 1 - year establishment and over 200 million current scale. Calculate sensitivity scores of economic, liquidity, and credit factors monthly, adjust scores according to the latest indicators, and sum them up. If liquidity and credit deviate significantly, remove the liquidity score. Select the top 6 industry - themed indices and corresponding largest - scale ETFs for equal - weight allocation [6][7]. - Currently, with falling economic leading indicators, loose liquidity, and tightened credit, the portfolio is biased towards TMT and consumption. The February positions are shown in Table 1 [8]. - The portfolio has large fluctuations and outperformed the benchmark significantly in January [11]. 3.3 Macro + Momentum Industry Portfolio - Combine macro and momentum methods to address the left - side nature of macro - based strategies (low win - rate but high odds). Use clustering to group industry - themed indices and select the highest - rising product in each group in the past 6 months for equal - weight allocation [12]. - The momentum - selected industries still have a high proportion of cyclical industries. The February positions are shown in Table 3 [16]. - The portfolio has performed well this year and outperformed the CSI 300 significantly in January [17]. 3.4 Core - Satellite Portfolio - Design a "core - satellite" portfolio with the CSI 300 as the core to address the high volatility and rapid industry rotation of industry - themed ETFs [19]. - Calculate macro - sensitivities for broad - based, industry - themed, and Smart Beta ETFs, construct three stock portfolios, and weight them at 50%, 30%, and 20% respectively [19]. - The current allocation of broad - based ETFs is biased towards the Sci - tech Innovation Board and the ChiNext. The portfolio has performed stably, outperforming the benchmark in most months except December, and had significant excess returns in January 2026 [23][24]. 3.5 Trinity Style Rotation ETF Portfolio - The model currently favors the small - cap growth - high - quality segment. The factor exposures and historical performance are shown in Table 7 [26]. - The February positions are shown in Table 9 [31]. - The portfolio has achieved certain excess returns, especially in some months such as August 2025 and January 2026 [29].

Market Overview - The Hong Kong stock market exhibited a "structural differentiation" trend on February 10, with a strong wait-and-see sentiment before the holiday. The Hang Seng Index rose by 0.58% to 27,183.15 points, the Hang Seng Tech Index increased by 0.62% to 5,451.03 points, the National Enterprises Index climbed by 0.81% to 9,242.75 points, and the Red Chip Index gained 0.27% to 4,407.29 points [1] Individual Stock Highlights - Evergrande Property saw a significant increase of 5.36% to 1.18 HKD, driven by news of potential bidders submitting updated offers for the company's assets, indicating progress in the liquidation process [2] - The stock of Geekplus Technology surged by 11.37% to 28.02 HKD following the launch of its Gino 1 warehouse robot, which is expected to accelerate the adoption of unmanned warehouses [3] - Yiteng Jiahe rose nearly 7% due to the completion of the first dosing in Phase II clinical trials for its ANGPTL3 siRNA drug EDP167 [4] - Bubble Mart received a favorable outlook from Macquarie, with a reiterated "outperform" rating, projecting global sales to exceed 400 million units by 2025 [5] Sector Performance - The AI and robotics sector emerged as a strong focus, with multiple stocks experiencing significant gains, including MiniMax-WP and Zhiyuan, which saw increases of 24% and 11%, respectively [3] - Pharmaceutical and technology hardware stocks also showed positive performance, with notable gains from companies like Singularity and Gree Medical, benefiting from favorable policy changes and strategic investments [4] Institutional Insights - Dongwu Securities noted that despite increased inflows from southbound funds, overall trading volume in the Hong Kong market has decreased, influenced by global tech stock capital expenditure concerns [6] - Analysts from Jianyin International indicated that the valuation recovery of Hong Kong stocks is nearly complete, shifting the investment logic from "valuation recovery" to "new productive forces" [6] - Analysts emphasized that the continuous inflow of southbound funds could enhance market sentiment and strengthen the pricing power of mainland funds in the Hong Kong market [6]

Market Overview - The A-share market experienced narrow fluctuations with mixed performance among the three major indices, where the Shanghai Composite Index rose by 0.13% and the ChiNext Index fell by 0.37% [2] - The media sector led the gains, particularly driven by the human-shaped robot concept, while the commercial aerospace concept declined [2] Sector Performance - The film and cinema sector surged by 11.31% in a single day, with related concepts such as Sora, short drama games, and cultural media also seeing significant increases [4][5] - Year-to-date performance shows the film and cinema sector up by 35.45%, short drama games up by 31.08%, and Sora concept up by 25.25% [5] AI Software Impact - The AI software sector emerged as a key focus, particularly with the recent buzz around ByteDance's new video generation model, Seedance 2.0, which has significant implications for AI multi-modal applications and video generation [6] - The model's breakthroughs are expected to lower production costs and technical barriers, enhancing efficiency in generating AI content [6] Market Sentiment and Trends - There is a notable trend of market participants seeking similarities in past performance, as seen with the DeepSeek index's significant rise last year, which has led to speculation about the potential for similar gains with the current "SD" concept [7][9] - The current market sentiment is influenced by the upcoming Chinese New Year, with investors looking for sectors that may gain traction during this period [9] Other Sector Highlights - The innovative drug sector showed strength, with a record transaction scale of $135.7 billion expected in 2025 for China's innovative drug license-out [14] - The PCB sector is anticipated to benefit from advancements in technology, particularly with applications in Nvidia and ASIC products [15] - The semiconductor equipment sector is projected to reach $791.7 billion in total sales by 2025, with a 26% growth expected in 2026 [16] - The humanoid robot sector remains active, with the launch of a new general-purpose robot platform that features advanced motion control capabilities [17]

Market Overview - The market showed slight differentiation today, with the Shanghai Composite Index closing up slightly while the ChiNext Index performed weaker. The total market turnover was 2.1 trillion, a decrease of over 100 billion compared to the previous trading day, with more stocks declining than rising [1] - The AI application sector saw a surge, with various sub-sectors such as film, short dramas, and multi-modal applications experiencing significant growth. The AI video generation model Seedance 2.0 from ByteDance gained traction during its testing phase [1] Sector Performance - The media sector, particularly film and digital media, attracted significant capital inflow, with leading stocks like Light Media and Sunshine Power seeing net inflows [3] - The biopharmaceutical sector also rose, led by innovative drug companies, with stocks like Wanbangde hitting the daily limit [1] - Conversely, retail and liquor stocks faced adjustments, with Hangzhou Jiebei hitting the daily limit down and Huangtai Liquor nearing the limit down [1] Key Stock Movements - The newly listed commercial aerospace stock, Electric Science and Technology Blue Sky, saw a dramatic increase of 750% on its first trading day, ultimately closing up nearly 600%, with a total market value exceeding 110 billion [1] Future Outlook - CITIC Securities indicated that the market is likely to experience moderate fluctuations due to the upcoming holiday, suggesting a consolidation phase [2] - Guoxin Securities noted that the current spring market may still have room for further development, recommending a strategy of holding stocks through the holiday [2][7] - Dongwu Securities highlighted that the week before the holiday is an optimal window for index positioning, with historical data suggesting a trend reversal typically begins in the last five trading days before the holiday [8]